Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
What are known side effects of benzocaine and lidocaine (if present) in topical burn gels?
Executive summary
Topical benzocaine commonly causes local irritation such as temporary stinging, burning, or redness; it also carries a rare but serious risk of methemoglobinemia that has prompted FDA warnings and case reports, especially with oral/spray formulations and in young children (examples of methemoglobin levels reported up to 69%) [1] [2] [3]. Topical lidocaine can produce similar local reactions (burning, itching, blistering) and—when used over large areas or improperly—carries systemic toxicity risks, but available sources emphasize lidocaine produces less methemoglobin than benzocaine in lab models [4] [5] [2].
1. Local skin reactions are the most common harms
Patient-facing references list temporary stinging, burning, redness, dryness, flaking, itching, and similar local reactions for both agents when applied to burns or skin: WebMD and Drugs.com report temporary stinging, burning, or redness as the most common benzocaine effects [1] [6], while Drugs.com’s lidocaine page warns of severe local reactions including burning, pain, swelling, itching, irritation, blistering, or other skin injury at the application site [4].
2. Benzocaine’s distinct and serious blood-risk: methemoglobinemia
Regulatory and case literature repeatedly flags benzocaine’s association with methemoglobinemia — a potentially life‑threatening reduction of oxygen‑carrying hemoglobin. The FDA reviewed cases and laboratory data and urged reporting after finding benzocaine generated more methemoglobin than lidocaine in red‑cell models; pediatric and ED case series document severe, sometimes near‑lethal methemoglobin levels (examples cited as high as 69%) after topical benzocaine exposure [2] [3] [7].
3. Who appears most at risk and why regulators warn caution
FDA analysis and poison‑control literature emphasize oral spray and high‑concentration benzocaine formulations, and pediatric exposures (teething products or “burn creams” applied by caregivers) as common settings for harm [2] [3]. StatPearls and FDA communications note benzocaine concentrations up to 20% in sprays and document that mucosal application or large‑area use raises systemic exposure risk [8] [2].
4. Lidocaine: local adverse effects plus systemic toxicity with misuse
Sources list local adverse effects for topical lidocaine similar to benzocaine (irritation, burning, blistering) and warn of more serious toxicity when used over large areas, with occlusion, or in high doses; adverse systemic events including CNS or cardiac effects are possible with excessive absorption, and lidocaine should be used cautiously in patients with certain comorbidities [4] [5] [9]. The Mayo Clinic and WebMD pages underscore the need for caution and monitoring in vulnerable populations [5] [9].
5. Comparative signal: benzocaine generates more methemoglobin than lidocaine in models
FDA‑cited lab work and reviews conclude benzocaine produces more methemoglobin than lidocaine in red‑cell models—a key rationale for regulatory concern and for advising caution, especially with OTC benzocaine oral products [2] [10]. Available sources do not claim lidocaine is risk‑free, but they note the relative methemoglobin signal is stronger for benzocaine [2].
6. Severe, rare systemic events and misuse scenarios
Medscape and case reviews document reports of irregular heartbeats, respiratory depression, seizures, and death after large‑area or prolonged application of topical anesthetics without professional supervision—an implicit warning against overapplication, occlusion, or use on extensive burns or damaged mucosa [7] [6]. For benzocaine specifically, pediatric case reports and poison‑control data show serious outcomes when caregivers applied products to children [3] [2].
7. Practical takeaways and gaps in reporting
Clinically: expect mostly local irritation from either agent; treat benzocaine with particular caution for mucosal use, sprays, high concentrations, and in children because of methemoglobinemia reports and FDA action [1] [2]. For lidocaine, avoid large-area or prolonged use and follow product directions; be alert for blistering or severe local reactions that require medical attention [4] [9]. Available sources do not mention long‑term chronic systemic effects from appropriately used topical burn gels beyond these acute/rare events — not found in current reporting.
Limitations: this summary uses provided consumer and clinical sources and case series; it does not incorporate additional regulatory updates or product‑specific label changes published outside the supplied set [1] [2] [3].